These clinicopathological results are consistent with our in vitro data, which showed that RHBDD1 deletion remarkably inhibits breast cancer cell proliferation and migration/invasion, respectively, in both ER-positive MCF7 and Triple-negative MDA-MB-231 cell lines. The gene discussed is RHBDD1; the disease is breast cancer.